Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Overview of attention for article published in Frontiers in Pharmacology, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 18,109 followers.

ダパグリフロジン aNNT:42 (34–59)エンパグリフロジン aNNT:42 (33–66) これは調節されてる値？？ https://t.co/4ehZ2WxPC3 各試験で計算してみたらNNTがダパ18.9とエンパ26.3だったんだが…

エンパグリフロジンの適用拡大で話題ですが・・・・ Dapagliflozin versus empagliflozin in patients with chronic kidney disease https://t.co/up62xTNMAk

New NNT→Dapagliflozin versus empagliflozin in patients with chronic kidney disease https://t.co/zm5WSloGjw

RT @Miguel_A_Maria: Dapagliflozin versus empagliflozin in patients with chronic kidney disease https://t.co/laydEMD5T9 Empa en diabetes htt…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.